Cargando…
Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension
PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463398/ https://www.ncbi.nlm.nih.gov/pubmed/34003319 http://dx.doi.org/10.1007/s00062-021-01024-2 |
_version_ | 1784572396513001472 |
---|---|
author | Belachew, Nebiyat F. Baschung, Severin Almiri, William Encinas, Ruben Kaesmacher, Johannes Dobrocky, Tomas Schankin, Christoph J. Abegg, Mathias Piechowiak, Eike I. Raabe, Andreas Gralla, Jan Mordasini, Pasquale |
author_facet | Belachew, Nebiyat F. Baschung, Severin Almiri, William Encinas, Ruben Kaesmacher, Johannes Dobrocky, Tomas Schankin, Christoph J. Abegg, Mathias Piechowiak, Eike I. Raabe, Andreas Gralla, Jan Mordasini, Pasquale |
author_sort | Belachew, Nebiyat F. |
collection | PubMed |
description | PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(TM) stent (PP). METHODS: A total of 15 patients with IIH (median age 28.7 years) were reviewed retrospectively. Technical aspects as well as peri- and postinterventional complication rates were examined in patients treated with CP (n = 10) and the PP (n = 5). Improvements in cerebrospinal fluid opening pressure (CSF OP), transstenotic pressure gradient (TSPG) and clinical symptoms were also assessed. RESULTS: Stent delivery was easier and more successful with the CP than the PP (difficult/failed stent delivery 0.0% versus 57.1%) and consequently achieved with less attempts (≥ 2: 0.0% versus 40.0%). No severe peri- or postinterventional complications or instances of in-stent thrombosis and/or stenosis were observed during follow-up. Improvement of CSF OP and TSPG immediately after VSS as well as at 6‑month follow-up was comparable between the CP and PP group. Both groups showed substantial and similar decreases in intensity and frequency of headache. Almost all patients with other IIH-related symptoms showed either improvement or complete resolution of those symptoms after VSS. All patients who were available for interview (n = 12/15) reported a substantial improvement in quality of life. CONCLUSION: VSS using the CP seems to be safe and effective. The CP may reduce the risk of difficult or failed stent delivery in patients with challenging intracranial venous anatomy. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01024-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-8463398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-84633982021-10-08 Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension Belachew, Nebiyat F. Baschung, Severin Almiri, William Encinas, Ruben Kaesmacher, Johannes Dobrocky, Tomas Schankin, Christoph J. Abegg, Mathias Piechowiak, Eike I. Raabe, Andreas Gralla, Jan Mordasini, Pasquale Clin Neuroradiol Original Article PURPOSE: We hypothesized that due to its specific characteristics, the Casper(TM) RX carotid stent (CP) might be particularly suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we compared it to the commonly used Precise Pro RX(TM) stent (PP). METHODS: A total of 15 patients with IIH (median age 28.7 years) were reviewed retrospectively. Technical aspects as well as peri- and postinterventional complication rates were examined in patients treated with CP (n = 10) and the PP (n = 5). Improvements in cerebrospinal fluid opening pressure (CSF OP), transstenotic pressure gradient (TSPG) and clinical symptoms were also assessed. RESULTS: Stent delivery was easier and more successful with the CP than the PP (difficult/failed stent delivery 0.0% versus 57.1%) and consequently achieved with less attempts (≥ 2: 0.0% versus 40.0%). No severe peri- or postinterventional complications or instances of in-stent thrombosis and/or stenosis were observed during follow-up. Improvement of CSF OP and TSPG immediately after VSS as well as at 6‑month follow-up was comparable between the CP and PP group. Both groups showed substantial and similar decreases in intensity and frequency of headache. Almost all patients with other IIH-related symptoms showed either improvement or complete resolution of those symptoms after VSS. All patients who were available for interview (n = 12/15) reported a substantial improvement in quality of life. CONCLUSION: VSS using the CP seems to be safe and effective. The CP may reduce the risk of difficult or failed stent delivery in patients with challenging intracranial venous anatomy. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01024-2) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2021-05-18 2021 /pmc/articles/PMC8463398/ /pubmed/34003319 http://dx.doi.org/10.1007/s00062-021-01024-2 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Belachew, Nebiyat F. Baschung, Severin Almiri, William Encinas, Ruben Kaesmacher, Johannes Dobrocky, Tomas Schankin, Christoph J. Abegg, Mathias Piechowiak, Eike I. Raabe, Andreas Gralla, Jan Mordasini, Pasquale Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title | Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title_full | Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title_fullStr | Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title_full_unstemmed | Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title_short | Casper Versus Precise Stent for the Treatment of Patients with Idiopathic Intracranial Hypertension |
title_sort | casper versus precise stent for the treatment of patients with idiopathic intracranial hypertension |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463398/ https://www.ncbi.nlm.nih.gov/pubmed/34003319 http://dx.doi.org/10.1007/s00062-021-01024-2 |
work_keys_str_mv | AT belachewnebiyatf casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT baschungseverin casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT almiriwilliam casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT encinasruben casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT kaesmacherjohannes casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT dobrockytomas casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT schankinchristophj casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT abeggmathias casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT piechowiakeikei casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT raabeandreas casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT grallajan casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension AT mordasinipasquale casperversusprecisestentforthetreatmentofpatientswithidiopathicintracranialhypertension |